All insights
Funding·5 min read·

Recursion Pharmaceuticals Secures $200M from Nvidia Partnership for AI Drug Discovery Platform

Recursion Pharmaceuticals raises $200M through expanded partnership with Nvidia to accelerate AI-driven drug discovery. Deal includes access to Nvidia DGX SuperPOD supercomputing infrastructure and BioNeMo AI models for molecular design.

World Health AI Summit

<div class="space-y-8"> <div class="bg-gradient-to-br from-green-900/20 to-emerald-900/20 rounded-2xl p-8 border border-green-700/30"> <h2 class="text-2xl font-bold text-white mb-4">Strategic Investment</h2> <p class="text-gray-100 text-lg leading-relaxed"> <strong class="text-white">Recursion Pharmaceuticals</strong> secured <strong class="text-white">$200 million</strong> from Nvidia in a strategic partnership accelerating AI-powered drug discovery. The collaboration combines Recursion's biological data platform with Nvidia's supercomputing infrastructure and AI models. </p> </div> <div class="grid grid-cols-1 md:grid-cols-2 gap-6 my-10"> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Investment Size</h4> <div class="text-3xl font-bold text-green-400 mb-1">$200M</div> <p class="text-sm text-gray-400">Strategic partnership</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Data Library</h4> <div class="text-3xl font-bold text-blue-400 mb-1">50TB</div> <p class="text-sm text-gray-400">Biological data</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">Drug Candidates</h4> <div class="text-3xl font-bold text-purple-400 mb-1">12</div> <p class="text-sm text-gray-400">In clinical trials</p> </div> <div class="bg-gray-900/50 rounded-xl p-6 border border-gray-700"> <h4 class="text-sm font-semibold text-gray-400 uppercase tracking-wide mb-3">GPU Infrastructure</h4> <div class="text-lg font-bold text-orange-400 mb-1">BioNeMo</div> <p class="text-sm text-gray-400">Nvidia platform access</p> </div> </div> <div class="my-12"> <h2 class="text-3xl font-bold text-white mb-6 pb-4 border-b border-gray-800">Platform Capabilities</h2> <div class="space-y-4"> <div class="bg-gradient-to-r from-blue-900/20 to-cyan-900/20 rounded-lg p-5 border-l-4 border-blue-500"> <h4 class="text-lg font-bold text-white mb-2">Cellular Imaging</h4> <p class="text-gray-300">High-throughput microscopy analyzing drug effects</p> </div> <div class="bg-gradient-to-r from-purple-900/20 to-pink-900/20 rounded-lg p-5 border-l-4 border-purple-500"> <h4 class="text-lg font-bold text-white mb-2">AI Predictions</h4> <p class="text-gray-300">Machine learning identifying therapeutic targets</p> </div> <div class="bg-gradient-to-r from-green-900/20 to-emerald-900/20 rounded-lg p-5 border-l-4 border-green-500"> <h4 class="text-lg font-bold text-white mb-2">Virtual Screening</h4> <p class="text-gray-300">Billions of molecules evaluated in silico</p> </div> <div class="bg-gradient-to-r from-orange-900/20 to-red-900/20 rounded-lg p-5 border-l-4 border-orange-500"> <h4 class="text-lg font-bold text-white mb-2">Nvidia BioNeMo</h4> <p class="text-gray-300">GPU-accelerated generative AI for drug design</p> </div> </div> </div> <div class="bg-gradient-to-br from-orange-900/30 to-red-900/30 rounded-2xl p-8 border border-orange-700/50 my-12"> <h3 class="text-2xl font-bold text-white mb-4">Market Implications</h3> <p class="text-gray-100 text-lg leading-relaxed"> This partnership validates the convergence of AI infrastructure and biotech R&D, positioning Recursion to accelerate discovery timelines from years to months while Nvidia gains strategic foothold in pharmaceutical AI market. </p> </div> <div class="border-t border-gray-800 pt-6"> <p class="text-sm text-gray-500 italic"> <strong>Source:</strong> Recursion Pharmaceuticals, Nvidia Press Release, August 2024 </p> </div> </div>

This briefing summarises publicly available research and reporting for information only. It is not medical, investment, or legal advice. Follow the references above to the primary sources.